Kidney News sat down with Steven G. Achinger, MD, Managing Partner & Chairman of the Board at Watson Clinic LLP in Lakeland, FL, to speak about his recent move into management after 11 years of clinical nephrology practice, including how he made the decision and any advice he has for those considering a similar move.

Accreditation organizations are independent organizations with no direct ties to a government entity. They apply to CMS for deemed status and must report survey information to CMS.

Kidney News interviewed Christian Schafmeister, PhD, Department of Chemistry, College of Science and Technology, Temple University, about his KidneyX Prize, “Atomically Precise Membranes for High-Flux and Selective Removal of Blood Toxins” during hemodialysis. Schafmeister presented the work for the Phase I Redesign Dialysis Prize at the inaugural KidneyX Summit in Washington, DC, on April 29, 2019.

Kidney News interviewed Jeff Ross, PhD, CEO of Miromatrix Medical, about the company’s work to bioengineer new kidney grafts consisting of human cells grown in pig extracellular matrix scaffolds. Ross presented the work, “Building New Kidneys,” at the inaugural KidneyX Summit in Washington, DC, on April 29, 2019.

Hypoxia-inducible factor prolyl-hydroxylase inhibitors (commonly known as HIF stabilizers or PHIs) belong to a new class of orally administered drugs to treat anemia in patients with CKD.

To boldly restate the obvious, trials in anemia have provided surprising, controversial, and dramatic, practice-changing results for the last 20 years. The latest key trial to add to our knowledge on how to treat the anemia of kidney disease is the PIVOTAL trial (1).

The editors hope that this issue of ASN Kidney News focusing on anemia and its management will allow readers to review lessons learned from our use of rEPO and to take pause as we thoughtfully embark on anemia treatment strategies utilizing newer agents that may soon be available.